Main Treatment Choices in the 2 First Lines of Therapy for Multiple Myeloma in Patients with High Risk Cytogenetics: Lesson from the Real World in the EU5 Countries and the USA

被引：0
|
作者：
Blin, Nicolas [1 ]
Mai, Christine [2 ]
Ertl, Siegfried [3 ]
Schneider, Elodie [2 ]
Leberre, Marine [2 ]
Yilmaz, Melissa [2 ]
机构：
[1] Nantes Univ Hosp, Dept Hematol, Nantes, France
[2] AplusA, Lyon, France
[3] AplusA, London, England
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-189254
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 44 条
  • [1] Real-World Data on Frontline (FL) Treatments in Multiple Myeloma (MM) Patients across EU5 Countries
    Anjo, Joana
    Rider, Alex
    Bailey, Abigail
    Gaudig, Maren
    [J]. BLOOD, 2018, 132
  • [2] Impact of Ethnicity in Treatment Choice for Multiple Myeloma in the 3 First Lines of Therapy: Data from Observational Retrospective Real-World Study in the USA
    Blin, Nicolas
    Mai, Christine
    Ertl, Siegfried
    Schneider, Elodie
    Leberre, Marine
    Yilmaz, Melissa
    [J]. BLOOD, 2023, 142
  • [3] ACTUAL USE IN REAL WORLD SETTING OF ANTI-BCMA CAR T CELLS IN RELAPSED/REFRACTORY MULTIPLE MYELOMA IN EU5 COUNTRIES AND IN THE US
    Mai, C.
    Blin, N.
    Ertl, S.
    Schneider, E.
    Leberre, M.
    Yilmaz, M.
    Vidal, M.
    [J]. VALUE IN HEALTH, 2023, 26 (12) : S316 - S316
  • [4] Verification of guideline conform mCRC treatment with EGFR inhibitors with real-world evidence data from EU5 countries
    Hoyer, L.
    Schmidt, N.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 : 165 - 165
  • [5] REAL-WORLD USAGE OF BORTEZOMIB IN COMBINATION WITH THALIDOMIDE AND DEXAMETHASONE (VTD) AS FRONTLINE (FL) TREATMENT IN STEM CELL TRANSPLANT (SCT) ELIGIBLE MULTIPLE MYELOMA (MM) PATIENTS ACROSS EU5 COUNTRIES
    Anjo, J.
    Rider, A.
    Bailey, A.
    Gaudig, M.
    [J]. VALUE IN HEALTH, 2018, 21 : S70 - S70
  • [6] REAL-WORLD USAGE OF BORTEZOMIB IN COMBINATION WITH MELPHALAN AND PREDNISONE (VMP) AS FRONTLINE (FL) TREATMENT IN STEM CELL TRANSPLANT (SCT) INELIGIBLE MULTIPLE MYELOMA (MM) PATIENTS ACROSS EU5 COUNTRIES
    Anjo, J.
    Rider, A.
    Gaudig, M.
    [J]. VALUE IN HEALTH, 2018, 21 : S72 - S72
  • [7] Patient-reported outcomes and burden of disease in paediatric patients with psoriasis: real-world data from the EU5 and USA
    Seyger, M.
    Paller, A.
    Sticherling, M.
    Bachhuber, T.
    Fang, J.
    Hetherington, J.
    Lucas, J.
    Meakin, S.
    Richardson, C.
    Augustin, M.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (01) : E28 - E29
  • [8] Real-World Clinical Outcomes of Multiple Myeloma Patients with High-Risk Cytogenetics Treated with Dararvd, Single Center Experience
    Aqeel, Sheeba Ba
    Taneja, Alankrita
    Groman, Adrienne
    Parker, Sarah
    Jatwani, Karan
    Roy, Arya Mariam
    Attwood, Kristopher
    McCarthy, Philip L.
    Hillengass, Jens
    [J]. BLOOD, 2022, 140 : 13216 - 13217
  • [9] The relationship of extramedullary disease and high-risk cytogenetics on real-world outcomes among patients with triple-class exposed multiple myeloma
    Meche, Aster
    Rondeau, Felix
    Vekeman, Francis
    Ren, Jinma
    Schepart, Alexander
    Hlavacek, Patrick
    Farrell, James
    Aydin, Didem
    Nador, Guido
    DiBonaventura, Marco
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S173 - S174
  • [10] Real-World Treatment Patterns and Outcomes of Patients with Functional High-Risk (Early Relapse) Multiple Myeloma
    Belli, Andrew J.
    Hansen, Eric
    Kansagra, Ankit
    Dilwali, Keshava
    Wang, Ching-Kun
    [J]. BLOOD, 2020, 136
12345